Based on the Dyne Therapeutics Inc stock forecast from 7 analysts, the average analyst target price for Dyne Therapeutics Inc is USD 40.50 over the next 12 months. Dyne Therapeutics Inc’s average analyst rating is Strong Buy. Stock Target Advisor’s own stock analysis of Dyne Therapeutics Inc is Bearish, which is based on 2 positive signals and 6 negative signals. At the last closing, Dyne Therapeutics Inc’s stock price was USD 23.70. Dyne Therapeutics Inc’s stock price has changed by +0.19% over the past week, -9.08% over the past month and +122.70% over the last year.
No recent analyst target price found for Dyne Therapeutics Inc
No recent average analyst rating found for Dyne Therapeutics Inc
Company Overview Dyne Therapeutics Inc
Dyne Therapeutics, Inc., a clinical-stage muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics. Dyne Therapeutics, Inc. was incorporated in 2017 and is headquartered in Waltham, Massachusetts. Read Less
Dyne Therapeutics, Inc., a clinical-stage muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It is developing a portfolio of muscle disease therapeutics, including program...Read More
Frequently Asked Questions About Dyne Therapeutics Inc (DYN) Stock
Based on ratings from 7 analysts Dyne Therapeutics Inc's stock is Strong Buy. Stock Target Advisor's fundamental analysis is Bearish. The stock has 8 buy, sell and hold ratings.
Unfortunately we do not have enough data on DYN's stock to indicate if its a good dividend stock.
Based on targets from 7 analysts, the average taret price for DYN is USD 40.50 over the next 12 months. The maximum analyst target price is USD 56 while the minimum anlayst target price is USD 29.
DYN stock's Price/Earning ratio is 4.27.
Our analysis grades DYN stock's Price / Earning ratio at F. This means that DYN stock's Price/Earning ratio is above 44.99999999999999% of the stocks in the Biotechnology sector in the NSD exchange.
Based on this DYN may be fairly valued for its sector
The last closing price of DYN's stock was USD 23.70.
The most recent market capitalization for DYN is USD 2.06B.
Based on targets from 7 analysts, the average taret price for DYN is projected at USD 40.50 over the next 12 months.
This means that DYN's stock price may go up by +70.92% over the next 12 months.
Following are ETFs with the highest allocation to Dyne Therapeutics Inc's stock :
As per our most recent records Dyne Therapeutics Inc has 141 Employees.
Dyne Therapeutics Inc's registered address is 1560 Trapelo Road, Waltham, MA, United States, 02451.
You can get more information about it from Dyne Therapeutics Inc's website at https://www.dyne-tx.com.
Heading 1
Heading 2
Heading 3
Heading 4
Heading 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Stock Target Advisor's Analysis
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
What to like
Superior risk adjusted returns
This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.
High market capitalization
This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.
What not to like
Overpriced compared to book value
The stock is trading high compared to its peers median on a price to book value basis.
Below median total returns
The company has under performed its peers on annual average total returns in the past 5 years.
High volatility
The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.
Negative cashflow
The company had negative total cash flow in the most recent four quarters.
Negative free cash flow
The company had negative total free cash flow in the most recent four quarters.
Low Earnings Growth
This stock has shown below median earnings growth in the previous 5 years compared to its sector
Add to Watchlists
loading..
Thank you for Sharing your Stock Targets for DYN !
Loading...
Please login to proceed
Sorry - extended search is only available for registered users.
Stocktwits
